TM
INO icon

Triatomic Management’s Inovio Pharmaceuticals INO Stock Holding History

Triatomic Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,583
Closed -$367K – 60
2022
Q4 		$367K Hold
19,583
– – 0.31% 37
2022
Q3 		$405K Hold
19,583
– – 0.23% 36
2022
Q2 		$407K Hold
19,583
– – 0.37% 31
2022
Q1 		$844K Buy
+19,583
New +$882K 0.69% 29

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Triatomic Management's INO Position: Q1 2023 in Review

Triatomic Management sold out of Inovio Pharmaceuticals (INO) in Q1 2023, closing a stake of 19,583 shares — an estimated $367K sold.

Triatomic Management first reported a position in INO in Q1 2022 and held it in 4 quarters. The position peaked at $844K in Q1 2022. 174 funds tracked by Wall St. Rank hold INO as of Q1 2023.

  • Triatomic Management reported no remaining Inovio Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Triatomic Management sold 19,583 Inovio Pharmaceuticals shares in Q1 2023, an estimated $367K.
  • Triatomic Management first reported a position in Inovio Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Triatomic Management's Inovio Pharmaceuticals position peaked at $844K in Q1 2022.
  • 174 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2023.

Based on Triatomic Management's 13F filing for Q1 2023, filed 3 May 2023.